In the race to develop a coronavirus treatment, Regeneron thinks it has the inside track
A new treatment promises to make little people taller. Is it an insult to ‘dwarf pride’?
Is sexual desire a medical issue? An experimental drug for women revives an intense debate
At MIT, a bitter dispute over research puts a scientist’s prestige on the line
So good it hurts: Why drug makers looking to replace opioids want to keep some pain in the picture
Three years after steep price hike, Martin Shkreli’s drug company is losing money, documents show
Biotech tries to break bread with Silicon Valley’s disruptors. It’s awkward
How will biotech’s latest bubble go pop? We asked some experts
Biotech hedge fund titan Sam Isaly harassed, demeaned women for years, former employees say
Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine
That’s ‘what I call’ innovation: The bons mots of Patrick Soon-Shiong